Anticancer Drugs Compared to No Anticancer Drugs in Patients with Advanced Hepatobiliary Cancer: A Mapping Review and Evidence Gap Map.
antineoplastic agents
bile duct neoplasms
biological therapy
gallbladder neoplasms
immunotherapy
liver neoplasms
palliative care
Journal
Clinical epidemiology
ISSN: 1179-1349
Titre abrégé: Clin Epidemiol
Pays: New Zealand
ID NLM: 101531700
Informations de publication
Date de publication:
2023
2023
Historique:
received:
20
07
2023
accepted:
14
10
2023
medline:
29
11
2023
pubmed:
29
11
2023
entrez:
29
11
2023
Statut:
epublish
Résumé
Despite being commonly recommended, the impact of anticancer drugs (ACDs) on patient-important outcomes beyond survival for advanced hepatobiliary cancers (HBCs) may not have been sufficiently assessed. We aim to identify and map the evidence regarding ACDs versus best supportive care (BSC) for advanced HBCs, considering patient-centered outcomes. In this mapping review, we included systematic reviews, randomized controlled trials, quasi-experimental, and observational studies comparing ACDs (chemotherapy, immunotherapy, biological/targeted therapy) versus BSC for advanced HBCs. We searched MEDLINE (PubMed), EMBASE (Ovid), Cochrane Library, Epistemonikos, PROSPERO and clinicaltrials.gov for eligible studies. Two reviewers performed the screening and data extraction processes. We developed evidence maps for each type of cancer. We included 87 studies (60 for advanced liver cancer and 27 for gallbladder or bile duct cancers). Most of the evidence favored ACDs for survival outcomes, and BSC for toxicity. We identified several evidence gaps for non-survival outcomes, including quality of life or quality of end-of-life care. Patient-important outcomes beyond survival in advanced HBCs are insufficiently assessed by the available evidence. Future studies need to address these gaps to better inform decision-making processes.
Identifiants
pubmed: 38025841
doi: 10.2147/CLEP.S431498
pii: 431498
pmc: PMC10644842
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1069-1085Informations de copyright
© 2023 Requeijo et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests in this work.
Références
Clin Exp Med. 2022 Feb;22(1):65-74
pubmed: 34146196
Ther Adv Med Oncol. 2020 Jul 23;12:1758835920937422
pubmed: 32754228
JCO Oncol Pract. 2022 Aug;18(8):e1357-e1366
pubmed: 34855459
Cancers (Basel). 2023 Jan 26;15(3):
pubmed: 36765723
PLoS One. 2014 Jul 02;9(7):e101145
pubmed: 24988441
Ann Oncol. 2018 Jun 1;29(6):1402-1408
pubmed: 29659672
Hepatol Int. 2022 Oct;16(5):1199-1207
pubmed: 35986846
J Clin Oncol. 2013 Oct 1;31(28):3509-16
pubmed: 23980090
Indian J Surg Oncol. 2016 Mar;7(1):25-31
pubmed: 27065678
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
BMC Med Res Methodol. 2011 Jun 17;11:92
pubmed: 21682870
Am J Clin Oncol. 2021 Mar 1;44(3):93-98
pubmed: 33350678
Lancet Oncol. 2020 Jun;21(6):796-807
pubmed: 32416072
Lancet Oncol. 2019 Feb;20(2):282-296
pubmed: 30665869
BMC Palliat Care. 2020 Nov 30;19(1):184
pubmed: 33256786
Can Liver J. 2021 Aug 9;4(3):257-274
pubmed: 35992253
Lancet Oncol. 2009 Jan;10(1):25-34
pubmed: 19095497
Strahlenther Onkol. 2004 Dec;180(12):751-7
pubmed: 15592694
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv238-iv255
pubmed: 30285213
Jpn J Clin Oncol. 2007 Nov;37(11):843-51
pubmed: 17942578
Oncologist. 2013;18(4):379-80
pubmed: 23580239
Ann Oncol. 2015 Dec;26(12):2457-63
pubmed: 26386123
Front Oncol. 2021 Sep 28;11:736113
pubmed: 34650920
J Clin Oncol. 2010 Mar 1;28(7):1203-8
pubmed: 20124172
Eur J Cancer. 2014 May;50(7):1259-68
pubmed: 24485665
J Cancer. 2019 Aug 19;10(19):4671-4678
pubmed: 31528232
Cancer Med. 2020 Jan;9(1):141-150
pubmed: 31721465
Lancet Oncol. 2012 Feb;13(2):e77-82
pubmed: 22300862
Trials. 2016 Sep 13;17(1):449
pubmed: 27618914
Medicine (Baltimore). 2021 Sep 24;100(38):e27013
pubmed: 34559096
Syst Rev. 2023 Mar 15;12(1):45
pubmed: 36918977
Cancers (Basel). 2021 Jan 07;13(2):
pubmed: 33430312
Oncologist. 2009 Jan;14(1):95-100
pubmed: 19144678
Medicine (Baltimore). 2016 Dec;95(49):e5591
pubmed: 27930578
Ann Oncol. 2023 Feb;34(2):127-140
pubmed: 36372281
Ann Oncol. 2016 Sep;27(suppl 5):v28-v37
pubmed: 27664259
J Clin Oncol. 2010 Oct 20;28(30):4581-6
pubmed: 20855823
Cancer Res Treat. 2018 Jul;50(3):791-800
pubmed: 28838033
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
JAMA. 2014 Jul 2;312(1):57-67
pubmed: 25058218
JAMA Oncol. 2015 Jul;1(4):430-2
pubmed: 26181248
Sci Rep. 2019 Apr 3;9(1):5548
pubmed: 30944390
Lancet Gastroenterol Hepatol. 2021 Jul;6(7):559-568
pubmed: 33971141
Cochrane Database Syst Rev. 2018 Apr 06;4:CD011746
pubmed: 29624208
J Clin Oncol. 2020 Jan 20;38(3):193-202
pubmed: 31790344
N Engl J Med. 2018 Jul 05;379(1):54-63
pubmed: 29972759
Oncology. 2004;66(2):138-42
pubmed: 15138366
JAMA Netw Open. 2021 Dec 1;4(12):e2136128
pubmed: 34870682
J Gastroenterol Hepatol. 2001 Apr;16(4):452-9
pubmed: 11354285
BMC Health Serv Res. 2014 Nov 21;14:579
pubmed: 25413154
Hepatol Res. 2021 Aug;51(8):880-889
pubmed: 33837620
Clin Radiol. 2021 Sep;76(9):709.e1-709.e6
pubmed: 34116796
J Gastrointest Oncol. 2021 Dec;12(6):2943-2951
pubmed: 35070420
Cancer Chemother Pharmacol. 2007 Jan;59(1):9-15
pubmed: 16614848
Hepatogastroenterology. 1998 Nov-Dec;45(24):2020-6
pubmed: 9951857
Medicine (Baltimore). 2019 Jun;98(25):e16074
pubmed: 31232945
Digestion. 2020;101(4):458-465
pubmed: 31129660
Chin Med Sci J. 2014 Mar;29(1):7-14
pubmed: 24698672
Ann Oncol. 2020 Sep;31(9):1169-1177
pubmed: 32464280
JAMA Oncol. 2020 Dec 1;6(12):e204930
pubmed: 33090186
J Hepatol. 2012 May;56(5):1097-1103
pubmed: 22245891
Ann Oncol. 1996 Aug;7(6):593-600
pubmed: 8879373
J Korean Med Sci. 2018 Oct 12;33(45):e283
pubmed: 30402048
Support Care Cancer. 2013 Mar;21(3):659-85
pubmed: 22936493
Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2011 Feb;33(1):51-7
pubmed: 21375938
J Hepatocell Carcinoma. 2021 Mar 22;8:145-154
pubmed: 33791250
BMC Palliat Care. 2017 Jan 25;16(1):10
pubmed: 28122560
J Clin Gastroenterol. 2019 Aug;53(7):486-494
pubmed: 30939505
Ann Intern Med. 2018 Oct 2;169(7):467-473
pubmed: 30178033
Lancet. 2017 Jan 7;389(10064):56-66
pubmed: 27932229
J Hepatol. 2016 Aug;65(2):289-95
pubmed: 27085251
Am J Clin Oncol. 2020 Jun;43(6):422-427
pubmed: 32118610
Hepatol Int. 2021 Feb;15(1):93-104
pubmed: 33420951
Lancet Gastroenterol Hepatol. 2017 Jun;2(6):407-417
pubmed: 28497756
Hepatobiliary Pancreat Dis Int. 2012 Oct;11(5):458-66
pubmed: 23060390
Acta Med Indones. 2012 Jul;44(3):228-32
pubmed: 22983078
Gastroenterology. 2021 Sep;161(3):879-898
pubmed: 34126063
J Patient Rep Outcomes. 2020 Sep 15;4(1):77
pubmed: 32930891
Trials. 2017 Jun 20;18(Suppl 3):280
pubmed: 28681707
J Gastrointestin Liver Dis. 2021 Jun 18;30(2):254-258
pubmed: 33951116
Hepatology. 2018 Jan;67(1):422-435
pubmed: 28881497
PLoS One. 2020 Mar 5;15(3):e0229492
pubmed: 32134981
Lancet Oncol. 2013 Jan;14(1):55-63
pubmed: 23182627
Lancet Oncol. 2021 May;22(5):690-701
pubmed: 33798493
J Cancer Res Clin Oncol. 2018 Feb;144(2):403-414
pubmed: 29249005
JAMA Netw Open. 2022 Jul 1;5(7):e2222721
pubmed: 35849393
Lancet Oncol. 2015 Jul;16(7):859-70
pubmed: 26095784
Oncologist. 2016 Sep;21(9):1113-20
pubmed: 27185615
Front Oncol. 2021 Dec 24;11:771045
pubmed: 35004289
J Pain Symptom Manage. 2013 Dec;46(6):925-37
pubmed: 23628515
J Clin Oncol. 2020 Dec 20;38(36):4317-4345
pubmed: 33197225
Cancer Sci. 2020 Oct;111(10):3759-3769
pubmed: 32716114
Cancer. 1988 Aug 1;62(3):479-83
pubmed: 2839280
J Clin Oncol. 2008 Aug 10;26(23):3860-6
pubmed: 18688053
Oncologist. 2011;16(12):1800-5
pubmed: 22128118
Acta Oncol. 2018 Jun;57(6):807-812
pubmed: 29265948
Lancet Oncol. 2018 May;19(5):682-693
pubmed: 29625879
BMC Med Res Methodol. 2019 Nov 4;19(1):203
pubmed: 31684874
Br J Cancer. 2015 Jun 30;113(1):6-11
pubmed: 26068397